Early involvement of death-associated protein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association with clinical progression

Doerthe Kuester, Altaf A. Dary, Christopher C. Moskalukz, Sabine Krueger, Frank Meyer, Roland Hartig, Manfred Stolte, Peter Malfertheiner, Hans Lippert, Albert Roessner, Wael El-Rifai, Regine Schneider-Stock

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Esophageal Barrett's adenocarcinoma (BA) develops through a multistage process, which is associated with the transcriptional silencing of tumor-suppressor genes by promoter CpG island hypermethylation. In this study, we explored the promoter hypermethylation and protein expression of proapoptotic deathassociated protein kinase (DAPK) during the multistep Barrett's carcinogenesis cascade. Early BA and paired samples of premalignant lesions of 61 patients were analyzed by methylation-specific polymerase chain reaction and immunohistochemistry. For the association of clinicopathological markers and protein expression, an immunohistochemical tissue microarray analysis of 66 additional BAs of advanced tumor stages was performed. Hypermethylation of DAPK promoter was detected in 20% of normal mucosa, 50% of Barrett's metaplasia, 53% of dysplasia, and 60% of adenocarcinomas, and resulted in a marked decrease in DAPK protein expression (P < .01). The loss of DAPK protein was significantly associated with advanced depth of tumor invasion and advanced tumor stages (P < .001). Moreover, the severity of reflux esophagitis correlated significantly with the hypermethylation rate of the DAPK promoter (P < .003). Thus, we consider DAPK inactivation by promoter hypermethylation as an early event in Barrett's carcinogenesis and suggest that a decreased protein expression of DAPK likely plays a role in the development and progression of BA.

Original languageEnglish (US)
Pages (from-to)236-245
Number of pages10
JournalNeoplasia
Volume9
Issue number3
DOIs
StatePublished - Jan 1 2007
Externally publishedYes

Fingerprint

Death-Associated Protein Kinases
Protein Kinases
Carcinogenesis
Adenocarcinoma
Proteins
Tissue Array Analysis
Neoplasms
Peptic Esophagitis
CpG Islands
Barrett Esophagus
Tumor Suppressor Genes
Methylation
Mucous Membrane
Immunohistochemistry
Polymerase Chain Reaction

Keywords

  • Barrett's adenocarcinoma
  • Barrett's metaplasia
  • DAPK
  • Inflammation
  • Reflux esophagitis

ASJC Scopus subject areas

  • Cancer Research

Cite this

Early involvement of death-associated protein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association with clinical progression. / Kuester, Doerthe; Dary, Altaf A.; Moskalukz, Christopher C.; Krueger, Sabine; Meyer, Frank; Hartig, Roland; Stolte, Manfred; Malfertheiner, Peter; Lippert, Hans; Roessner, Albert; El-Rifai, Wael; Schneider-Stock, Regine.

In: Neoplasia, Vol. 9, No. 3, 01.01.2007, p. 236-245.

Research output: Contribution to journalArticle

Kuester, D, Dary, AA, Moskalukz, CC, Krueger, S, Meyer, F, Hartig, R, Stolte, M, Malfertheiner, P, Lippert, H, Roessner, A, El-Rifai, W & Schneider-Stock, R 2007, 'Early involvement of death-associated protein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association with clinical progression', Neoplasia, vol. 9, no. 3, pp. 236-245. https://doi.org/10.1593/neo.06802
Kuester, Doerthe ; Dary, Altaf A. ; Moskalukz, Christopher C. ; Krueger, Sabine ; Meyer, Frank ; Hartig, Roland ; Stolte, Manfred ; Malfertheiner, Peter ; Lippert, Hans ; Roessner, Albert ; El-Rifai, Wael ; Schneider-Stock, Regine. / Early involvement of death-associated protein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association with clinical progression. In: Neoplasia. 2007 ; Vol. 9, No. 3. pp. 236-245.
@article{731a541286fe4c89b1488e01c0eb0307,
title = "Early involvement of death-associated protein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association with clinical progression",
abstract = "Esophageal Barrett's adenocarcinoma (BA) develops through a multistage process, which is associated with the transcriptional silencing of tumor-suppressor genes by promoter CpG island hypermethylation. In this study, we explored the promoter hypermethylation and protein expression of proapoptotic deathassociated protein kinase (DAPK) during the multistep Barrett's carcinogenesis cascade. Early BA and paired samples of premalignant lesions of 61 patients were analyzed by methylation-specific polymerase chain reaction and immunohistochemistry. For the association of clinicopathological markers and protein expression, an immunohistochemical tissue microarray analysis of 66 additional BAs of advanced tumor stages was performed. Hypermethylation of DAPK promoter was detected in 20{\%} of normal mucosa, 50{\%} of Barrett's metaplasia, 53{\%} of dysplasia, and 60{\%} of adenocarcinomas, and resulted in a marked decrease in DAPK protein expression (P < .01). The loss of DAPK protein was significantly associated with advanced depth of tumor invasion and advanced tumor stages (P < .001). Moreover, the severity of reflux esophagitis correlated significantly with the hypermethylation rate of the DAPK promoter (P < .003). Thus, we consider DAPK inactivation by promoter hypermethylation as an early event in Barrett's carcinogenesis and suggest that a decreased protein expression of DAPK likely plays a role in the development and progression of BA.",
keywords = "Barrett's adenocarcinoma, Barrett's metaplasia, DAPK, Inflammation, Reflux esophagitis",
author = "Doerthe Kuester and Dary, {Altaf A.} and Moskalukz, {Christopher C.} and Sabine Krueger and Frank Meyer and Roland Hartig and Manfred Stolte and Peter Malfertheiner and Hans Lippert and Albert Roessner and Wael El-Rifai and Regine Schneider-Stock",
year = "2007",
month = "1",
day = "1",
doi = "10.1593/neo.06802",
language = "English (US)",
volume = "9",
pages = "236--245",
journal = "Neoplasia (United States)",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Early involvement of death-associated protein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association with clinical progression

AU - Kuester, Doerthe

AU - Dary, Altaf A.

AU - Moskalukz, Christopher C.

AU - Krueger, Sabine

AU - Meyer, Frank

AU - Hartig, Roland

AU - Stolte, Manfred

AU - Malfertheiner, Peter

AU - Lippert, Hans

AU - Roessner, Albert

AU - El-Rifai, Wael

AU - Schneider-Stock, Regine

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Esophageal Barrett's adenocarcinoma (BA) develops through a multistage process, which is associated with the transcriptional silencing of tumor-suppressor genes by promoter CpG island hypermethylation. In this study, we explored the promoter hypermethylation and protein expression of proapoptotic deathassociated protein kinase (DAPK) during the multistep Barrett's carcinogenesis cascade. Early BA and paired samples of premalignant lesions of 61 patients were analyzed by methylation-specific polymerase chain reaction and immunohistochemistry. For the association of clinicopathological markers and protein expression, an immunohistochemical tissue microarray analysis of 66 additional BAs of advanced tumor stages was performed. Hypermethylation of DAPK promoter was detected in 20% of normal mucosa, 50% of Barrett's metaplasia, 53% of dysplasia, and 60% of adenocarcinomas, and resulted in a marked decrease in DAPK protein expression (P < .01). The loss of DAPK protein was significantly associated with advanced depth of tumor invasion and advanced tumor stages (P < .001). Moreover, the severity of reflux esophagitis correlated significantly with the hypermethylation rate of the DAPK promoter (P < .003). Thus, we consider DAPK inactivation by promoter hypermethylation as an early event in Barrett's carcinogenesis and suggest that a decreased protein expression of DAPK likely plays a role in the development and progression of BA.

AB - Esophageal Barrett's adenocarcinoma (BA) develops through a multistage process, which is associated with the transcriptional silencing of tumor-suppressor genes by promoter CpG island hypermethylation. In this study, we explored the promoter hypermethylation and protein expression of proapoptotic deathassociated protein kinase (DAPK) during the multistep Barrett's carcinogenesis cascade. Early BA and paired samples of premalignant lesions of 61 patients were analyzed by methylation-specific polymerase chain reaction and immunohistochemistry. For the association of clinicopathological markers and protein expression, an immunohistochemical tissue microarray analysis of 66 additional BAs of advanced tumor stages was performed. Hypermethylation of DAPK promoter was detected in 20% of normal mucosa, 50% of Barrett's metaplasia, 53% of dysplasia, and 60% of adenocarcinomas, and resulted in a marked decrease in DAPK protein expression (P < .01). The loss of DAPK protein was significantly associated with advanced depth of tumor invasion and advanced tumor stages (P < .001). Moreover, the severity of reflux esophagitis correlated significantly with the hypermethylation rate of the DAPK promoter (P < .003). Thus, we consider DAPK inactivation by promoter hypermethylation as an early event in Barrett's carcinogenesis and suggest that a decreased protein expression of DAPK likely plays a role in the development and progression of BA.

KW - Barrett's adenocarcinoma

KW - Barrett's metaplasia

KW - DAPK

KW - Inflammation

KW - Reflux esophagitis

UR - http://www.scopus.com/inward/record.url?scp=33947400177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947400177&partnerID=8YFLogxK

U2 - 10.1593/neo.06802

DO - 10.1593/neo.06802

M3 - Article

C2 - 17401463

AN - SCOPUS:33947400177

VL - 9

SP - 236

EP - 245

JO - Neoplasia (United States)

JF - Neoplasia (United States)

SN - 1522-8002

IS - 3

ER -